Compare · NVO vs TLPH
NVO vs TLPH
Side-by-side comparison of Novo Nordisk A/S (NVO) and Talphera Inc. (TLPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TLPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 4768.9x TLPH ($40.2M).
- Over the past year, NVO is down 45.0% and TLPH is up 71.2% - TLPH leads by 116.2 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for TLPH).
- NVO has more recent analyst coverage (25 ratings vs 2 for TLPH).
- Company
- Novo Nordisk A/S
- Talphera Inc.
- Price
- $41.52-3.32%
- $0.88+12.92%
- Market cap
- $191.82B
- $40.2M
- 1M return
- -9.35%
- +1.24%
- 1Y return
- -45.00%
- +71.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest TLPH
- H.C. Wainwright resumed coverage on Talphera with a new price target
- Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes
- Amendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.
- SEC Form 10-Q filed by Talphera Inc.
- Talphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.
- Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
- SEC Form DEFA14A filed by Talphera Inc.
- SEC Form DEF 14A filed by Talphera Inc.